Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to 0.09%.

  • Theravance Biopharma's Return on Capital Employed rose 500.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 500.0%. This contributed to the annual value of 0.14% for FY2024, which is 200.0% down from last year.
  • Theravance Biopharma's Return on Capital Employed amounted to 0.09% in Q3 2025, which was up 500.0% from 0.11% recorded in Q2 2025.
  • Theravance Biopharma's Return on Capital Employed's 5-year high stood at 0.09% during Q3 2025, with a 5-year trough of 0.92% in Q1 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.15% (2023), whereas its average is 0.34%.
  • In the last 5 years, Theravance Biopharma's Return on Capital Employed plummeted by -3100bps in 2021 and then surged by 6400bps in 2022.
  • Over the past 5 years, Theravance Biopharma's Return on Capital Employed (Quarter) stood at 0.78% in 2021, then skyrocketed by 82bps to 0.14% in 2022, then decreased by -7bps to 0.15% in 2023, then grew by 3bps to 0.15% in 2024, then surged by 41bps to 0.09% in 2025.
  • Its last three reported values are 0.09% in Q3 2025, 0.11% for Q2 2025, and 0.16% during Q1 2025.